New Medicines

Ulcerative colitis (UC); ASA refractory


New molecular entity
Dr Falk
Nestle Health Science

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase II Clinical Trials
Feb 17: Dr. Falk Pharma terminates the phase III PROTECT-1 trial in patients with UC due to IDMC recommendation.

Jul 16, PIII PROTECT 3 (NCT02849951) trial initiated. The PIII trials will support regulatory filings in 2019 in the EU and US.

The PROTECT 1 & 2 trials are currently recruiting participants.


LT-02 is a controlled release phosphatidylcholine preparation, an ester of phosphatidic acid and choline. As phosphatidylcholine is a constituent of mucus it is believed that it will provide protection to the stomach lining.
23 June 2011About 2 in 1,000 people in the UK develop UC. It can develop at any age but most commonly first develops between the ages of 10 and 40. About 1 /7 cases first develops in people >60. [2]
Ulcerative colitis (UC); ASA refractory